ME03482B - POLIPETPIDI KOJI SADRŽE NEGLIKOZILISANI Fc - Google Patents

POLIPETPIDI KOJI SADRŽE NEGLIKOZILISANI Fc

Info

Publication number
ME03482B
ME03482B MEP-2019-148A MEP2019148A ME03482B ME 03482 B ME03482 B ME 03482B ME P2019148 A MEP2019148 A ME P2019148A ME 03482 B ME03482 B ME 03482B
Authority
ME
Montenegro
Prior art keywords
glycosylized
polypetpides
containing non
polypetpides containing
Prior art date
Application number
MEP-2019-148A
Other languages
English (en)
Inventor
Gunasekaran Kannan
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ME03482B publication Critical patent/ME03482B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MEP-2019-148A 2013-03-14 2014-03-14 POLIPETPIDI KOJI SADRŽE NEGLIKOZILISANI Fc ME03482B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361784669P 2013-03-14 2013-03-14
EP14769541.5A EP2970441B1 (en) 2013-03-14 2014-03-14 AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES
PCT/US2014/028913 WO2014153063A1 (en) 2013-03-14 2014-03-14 AGLYCOSYLATED Fc-CONTAINING POLYPEPTIDES

Publications (1)

Publication Number Publication Date
ME03482B true ME03482B (me) 2020-01-20

Family

ID=50680166

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2019-162A ME03437B (me) 2013-03-14 2014-03-14 Muteini interleukina-2 za ekspanziju t-regulatornih ćelija
MEP-2019-148A ME03482B (me) 2013-03-14 2014-03-14 POLIPETPIDI KOJI SADRŽE NEGLIKOZILISANI Fc

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2019-162A ME03437B (me) 2013-03-14 2014-03-14 Muteini interleukina-2 za ekspanziju t-regulatornih ćelija

Country Status (40)

Country Link
US (8) US9546203B2 (me)
EP (2) EP2970423B1 (me)
JP (6) JP6480409B2 (me)
KR (5) KR102219124B1 (me)
CN (2) CN105143253B (me)
AP (1) AP2015008737A0 (me)
AR (1) AR095541A1 (me)
AU (2) AU2014236281B2 (me)
BR (1) BR112015022440B1 (me)
CA (3) CA3149348C (me)
CL (2) CL2015002669A1 (me)
CR (2) CR20200004A (me)
CY (2) CY1121767T1 (me)
DK (2) DK2970423T3 (me)
EA (2) EA034326B1 (me)
ES (2) ES2737598T3 (me)
HR (2) HRP20191075T1 (me)
HU (2) HUE044321T2 (me)
IL (2) IL241349B (me)
JO (1) JO3796B1 (me)
LT (2) LT2970423T (me)
MA (2) MA38477B1 (me)
ME (2) ME03437B (me)
MX (2) MX372880B (me)
MY (2) MY202248A (me)
NZ (1) NZ751148A (me)
PE (1) PE20151763A1 (me)
PH (1) PH12015502051A1 (me)
PL (2) PL2970423T3 (me)
PT (2) PT2970441T (me)
RS (2) RS58791B1 (me)
SG (2) SG11201507420UA (me)
SI (2) SI2970423T1 (me)
SM (2) SMT201900301T1 (me)
TN (1) TN2015000416A1 (me)
TR (2) TR201910802T4 (me)
TW (3) TWI784288B (me)
UA (1) UA119140C2 (me)
UY (2) UY40090A (me)
WO (2) WO2014153063A1 (me)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20190202898A9 (en) * 2012-04-03 2019-07-04 Novelmed Therapeutics, Inc. AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
EP2904014A4 (en) * 2012-10-04 2016-09-28 Novelmed Therapeutics Inc FOR ALTERNATIVE PATHS, SPECIFIC ANTIBODIES FOR THE TREATMENT OF HEMOLYTIC DISEASES
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
AU2014233494B2 (en) 2013-03-15 2018-10-04 Genentech, Inc. IL-22 polypeptides and IL-22 Fc fusion proteins and methods of use
PE20151923A1 (es) 2013-03-15 2016-01-14 Amgen Inc Anticuerpos humanos pac1
EP3508496A1 (en) 2014-02-06 2019-07-10 F. Hoffmann-La Roche AG Interleukin-2 fusion proteins and uses thereof
MX378790B (es) * 2014-07-21 2025-03-10 Delinia Inc Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades autoinmunes.
EP3482766B1 (en) 2014-08-11 2020-05-20 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
TW201620938A (zh) 2014-09-15 2016-06-16 安美基公司 雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
US10793613B2 (en) 2014-12-15 2020-10-06 Washington University Compositions and methods for targeted cytokine delivery
IL283764B2 (en) 2015-04-10 2024-01-01 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
AU2016246152A1 (en) * 2015-04-10 2017-11-02 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
CA2996691A1 (en) 2015-09-22 2017-03-30 Genentech, Inc. Expression of fc-containing proteins
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
MA43959A (fr) * 2016-02-03 2018-12-12 Amgen Res Munich Gmbh Constructions d'anticorps impliquant des cellules t bispécifiques psma et cd3
JP6959011B2 (ja) * 2016-02-03 2021-11-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｂｃｍａおよびｃｄ３に対する二重特異性を有するｔ細胞エンゲージ抗体コンストラクト
EP3411414A4 (en) 2016-02-05 2019-10-23 Washington University COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF
CN107287273B (zh) * 2016-03-31 2021-03-09 复旦大学附属妇产科医院 表达Tim-3的外周血NK细胞在制备自然流产生物标记物中的用途
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CN109071623B (zh) * 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
EP3475413B1 (en) 2016-06-22 2024-02-14 David Klatzmann Genetically modified t lymphocytes
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
KR101928981B1 (ko) * 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
WO2018089420A1 (en) 2016-11-08 2018-05-17 Delinia, Inc. Il-2 variants for the treatment of autoimmune diseases
EP3551749B1 (en) 2016-12-07 2023-09-27 East Carolina University Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells
CA3055200A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Compositions and methods for immunotherapy
JP7165717B2 (ja) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド 標的免疫寛容
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US10676516B2 (en) * 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2019112852A1 (en) * 2017-12-06 2019-06-13 Pandion Therapeutics, Inc. Targeted immunotolerance
US12269898B2 (en) 2017-10-04 2025-04-08 Amgen Inc. Transthyretin immunoglobulin fusions
PH12020550661A1 (en) 2017-11-21 2021-04-19 Univ Leland Stanford Junior Partial agonists of interleukin-2
KR102684426B1 (ko) * 2017-12-06 2024-07-11 팬디온 오퍼레이션스, 인코포레이티드 Il-2 뮤테인 및 그 용도
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP7765181B2 (ja) 2017-12-19 2025-11-06 ゼンコア インコーポレイテッド 改変されたｉｌ－２ ｆｃ融合タンパク質
WO2019131964A1 (ja) 2017-12-27 2019-07-04 協和発酵キリン株式会社 Ｉｌ－２改変体
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
CA3089853A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
EP3752178A1 (en) 2018-02-16 2020-12-23 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
TWI853807B (zh) * 2018-03-28 2024-09-01 美商必治妥美雅史谷比公司 介白素-2/介白素-2受體阿法融合蛋白及其使用方法
KR102170788B1 (ko) 2018-06-07 2020-10-28 한국생명공학연구원 무당질 항체 생산용 형질전환 마우스 및 이로부터 생산된 무당질 항체의 용도
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
JP7477885B2 (ja) 2018-06-22 2024-05-02 キュージーン インコーポレイテッド サイトカインをベースとした生理活性化薬剤およびその使用方法
CN120349426A (zh) 2018-06-22 2025-07-22 科优基因公司 白介素-2变体及其使用方法
JP7633810B2 (ja) 2018-07-02 2025-02-20 アムジェン インコーポレイテッド 抗ｓｔｅａｐ１抗原結合タンパク質
WO2020007937A1 (en) 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
ES3030707T3 (en) 2018-08-13 2025-07-01 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
MX2021005155A (es) 2018-11-01 2021-09-30 Shandong New Time Pharmaceutical Co Ltd Anticuerpo biespecífico y uso del mismo.
WO2020163782A2 (en) 2019-02-08 2020-08-13 The Uab Research Foundation Immunotherapy for the treatment and prevention of inflammatory bowel disease
JP7570338B2 (ja) 2019-02-15 2024-10-21 インテグラル・モレキュラー・インコーポレイテッド クローディン６抗体及びその使用
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
IL286711B2 (en) 2019-03-29 2025-10-01 Inst Curie Interleukin 2 variants with different biological activities
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CN114679909A (zh) 2019-05-20 2022-06-28 潘迪恩运营公司 MAdCAM靶向的免疫耐受
EP3980051A4 (en) * 2019-06-05 2023-09-13 Asher Biotherapeutics, Inc. FUSIONS OF MUTANT INTERLEUKIN-2 POLYPEPTIDES WITH ANTIGEN-BINDING MOLECULES TO MODULATE THE FUNCTION OF IMMUNE CELLS
EP3980464A1 (en) 2019-06-07 2022-04-13 Amgen Inc. Bispecific binding constructs with selectively cleavable linkers
SG11202112762TA (en) 2019-07-08 2021-12-30 Amgen Inc Multispecific transthyretin immunoglobulin fusions
EP4004025A1 (en) * 2019-07-26 2022-06-01 Visterra, Inc. Interleukin-2 agents and uses thereof
WO2021030483A1 (en) * 2019-08-12 2021-02-18 AskGene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
TW202120534A (zh) * 2019-08-13 2021-06-01 美商安進公司 用於擴增調節性ｔ細胞之介白素－２突變蛋白
WO2021049606A1 (ja) 2019-09-13 2021-03-18 協和キリン株式会社 ＤｃＲ３改変体
AU2020357550A1 (en) 2019-10-04 2022-05-05 Tae Life Sciences, Llc Antibody compositions comprising Fc mutations and site-specific conjugation properties
JP7543404B2 (ja) * 2019-11-20 2024-09-02 ジーアイ・セル・インコーポレイテッド Ｔ細胞培養用培地組成物及びこれを用いたｔ細胞の培養方法
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
CA3159468A1 (en) 2019-12-12 2021-06-17 David Klatzmann Interleukin 2 chimeric constructs
PE20221506A1 (es) 2019-12-17 2022-10-04 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia
US12091440B2 (en) 2019-12-20 2024-09-17 Regeneron Pharmaceuticals, Inc. IL2 and peptide-MHC complex fusion proteins and methods of use thereof
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
JP2023518443A (ja) * 2020-03-19 2023-05-01 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド インターロイキン２変異体およびその使用
WO2021185361A1 (zh) * 2020-03-19 2021-09-23 信达生物制药(苏州)有限公司 白介素2突变体及其用途
CN115667292A (zh) * 2020-04-06 2023-01-31 朗格生物技术公共公益股份有限公司 模块化合成受体和使用方法
GB2621482B (en) 2020-05-13 2024-09-04 Bonum Therapeutics Inc Compositions of protein complexes and methods of use thereof
CA3184351A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Bispecific binding constructs
US20230226203A1 (en) * 2020-06-18 2023-07-20 Proviva Therapeutics (Hong Kong) Limited Activatable procytokines
CN112048018B (zh) * 2020-08-31 2021-10-08 南方医科大学 一种嵌合t细胞生长因子及其应用
US12421286B2 (en) 2020-09-04 2025-09-23 Shandong Simcere Biopharmaceutical Co., Ltd. Il-2 mutant and application thereof
CA3195260A1 (en) 2020-10-29 2022-05-05 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
KR20230117397A (ko) 2020-12-03 2023-08-08 암젠 인크 다중 결합 도메인을 갖는 분자
CA3203977A1 (en) * 2020-12-04 2022-06-09 Visterra, Inc. Methods of using interleukin-2 agents
US20240034764A1 (en) * 2020-12-10 2024-02-01 Joint Stock Company "Biocad" Immunocytokine for activating human il-10ra receptor and use thereof
JP2024500900A (ja) * 2020-12-23 2024-01-10 メルク・シャープ・アンド・ドーム・エルエルシー 自己免疫疾患および炎症性疾患を治療するためのｉｌ－２ムテイン
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
MX2023013723A (es) 2021-05-19 2024-02-13 Asher Biotherapeutics Inc Polipeptidos de il-21 y construcciones dirigidas.
IL308733A (en) 2021-05-27 2024-01-01 Sanofi Sa Fc variant with increased affinity for Fc receptors and improved thermal stability
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
JP2024529340A (ja) 2021-07-14 2024-08-06 シンセカイン インコーポレイテッド 新生物疾患の細胞療法に使用するための方法および組成物
AU2022324624A1 (en) * 2021-08-06 2024-02-08 Amgen Inc. Isolation of therapeutic protein
KR20240113459A (ko) 2021-10-06 2024-07-22 일투 파마 염증 조직에 대한 표적화 특이성을 갖는 인터루킨 2 키메라 구성체
TW202323281A (zh) 2021-10-14 2023-06-16 美商泰尼歐生物公司 間皮素結合蛋白及其用途
EP4417626A4 (en) * 2021-10-14 2025-10-22 Latticon Suzhou Biopharmaceuticals Co Ltd NOVEL ANTIBODY-CYTOKINE FUSION PROTEIN, ITS PREPARATION METHOD AND USE
EP4440598A1 (en) * 2021-12-01 2024-10-09 Visterra, Inc. Methods of using interleukin-2 agents
WO2023148397A1 (en) 2022-02-07 2023-08-10 Vib Vzw Engineered stabilizing aglycosylated fc-regions
IL315173A (en) * 2022-02-22 2024-10-01 Univ Michigan Regents Materials and methods for the treatment of autoimmune disorders
TWI859752B (zh) * 2022-03-03 2024-10-21 大陸商海南先聲藥業有限公司 IL2突變體-抗體Fc嵌段融合蛋白的藥物組合物及其應用
EP4499846A1 (en) 2022-03-25 2025-02-05 Universität Zürich Adenoviral mediated targeting of activated immune cells
EP4532023A1 (en) 2022-05-27 2025-04-09 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
AU2023312905A1 (en) 2022-07-27 2025-01-16 Teneobio, Inc. Mesothelin binding proteins and uses thereof
IL319435A (en) 2022-09-12 2025-05-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Interleukin-2 for use in the treatment of autism spectrum disorder
EP4598958A1 (en) 2022-10-05 2025-08-13 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
AR130869A1 (es) 2022-10-25 2025-01-29 Ablynx Nv Polipéptidos de variantes de fc diseñados por glicoingeniería con función efectora aumentada
KR20250114330A (ko) 2022-11-30 2025-07-29 인테그럴 몰큘러 인코포레이티드 클라우딘 6을 표적하는 항체 및 이의 이중특이적 형식
CN120529914A (zh) 2023-01-09 2025-08-22 奥德赛治疗股份有限公司 抗tnfr2抗原结合蛋白及其用途
EP4669669A1 (en) 2023-02-21 2025-12-31 Teneobio, Inc. C-KIT BINDING PROTEINS, CHIMERIC ANTIGENIC RECEPTORS AND THEIR USES
US12286475B2 (en) 2023-07-31 2025-04-29 Sanofi Anti-GPRC5D antibodies and compositions
WO2025049858A1 (en) 2023-09-01 2025-03-06 Amgen Inc. Molecules for treatment of cancer
WO2025096842A2 (en) 2023-11-03 2025-05-08 Amgen Inc. Fibroblast targeting molecules
WO2025096843A1 (en) 2023-11-03 2025-05-08 Amgen Inc. Bispecific molecules
WO2025106529A2 (en) * 2023-11-14 2025-05-22 Cavalry Biosciences, Inc. Compositions for targeting muscle cells and uses thereof
WO2025133290A1 (en) 2023-12-21 2025-06-26 Temper Bio Protein for immune regulation
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
US20250313641A1 (en) 2024-04-09 2025-10-09 Amgen Inc. Agonistic anti-il-2rbg heavy-chain antibodies
WO2025217240A1 (en) 2024-04-10 2025-10-16 Odyssey Therapeutics, Inc. Anti-tnfr2 antigen-binding proteins and uses thereof
WO2025221954A1 (en) 2024-04-17 2025-10-23 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
WO2025259515A2 (en) 2024-06-11 2025-12-18 Amgen Inc. Combination treatment
WO2026006809A1 (en) 2024-06-27 2026-01-02 Odyssey Therapeutics, Inc. Multispecific molecules binding tnfr2 and cd25 and uses thereof
WO2026022712A1 (en) 2024-07-23 2026-01-29 Sanofi Cereblon ligase modulator and bcma nk cell engager combination therapy

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447A (en) 1846-04-04 Car- wheel
US233A (en) 1837-06-14 Improvement in plows
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988007054A1 (en) 1987-03-18 1988-09-22 Research Corporation Limited Complement-binding peptide
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
CA2062582C (en) 1991-03-27 1996-03-26 Tse-Wen Chang Methods and substances for recruiting therapeutic agents to solid tissues
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6239328B1 (en) 1992-10-05 2001-05-29 North Carolina State University Method for reducing expression variability of transgenes in plant cells
US6037525A (en) 1996-08-01 2000-03-14 North Carolina State University Method for reducing expression variability of transgenes in plant cells
FR2752462B1 (fr) 1996-08-14 1998-10-23 Essilor Int Procede d'incorporation d'additifs dans un article ophtalmique au moyen d'un fluide a l'etat supercritique
US6245974B1 (en) 1997-08-06 2001-06-12 North Carolina State University Matrix attachment regions
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6177612B1 (en) 1998-07-31 2001-01-23 Her Majesty The Queen In Right Of Canada, As Represented By The Department Of Agriculture And Agri-Food Canada Matrix attachment regions
AU762382B2 (en) 1998-09-29 2003-06-26 Pioneer Hi-Bred International, Inc. MAR/SAR elements flanking RSYN7-driven construct
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
BR0116024A (pt) * 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
US7259010B2 (en) 2000-12-15 2007-08-21 Pangen Biotech Inc. Expression vector for animal cell containing nuclear matrix attachment region of interferon beta
CA2435972C (en) 2001-01-26 2011-09-13 University Of Lausanne Matrix attachment regions and methods for use thereof
PL206975B1 (pl) 2001-12-04 2010-10-29 Merck Patent Gmbh Immunocytokiny o modulowanej selektywności oraz ich zastosowanie
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
ATE525395T1 (de) * 2003-06-12 2011-10-15 Lilly Co Eli Fusions proteine von glp-1-analoga
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
WO2005047512A2 (en) 2003-11-12 2005-05-26 Shering Corporation Plasmid system for multigene expression
JP2007527242A (ja) 2004-03-05 2007-09-27 カイロン コーポレーション 治療剤の患者耐容性を予測するためのインビトロ試験システム
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
AU2006244497B2 (en) * 2005-05-06 2011-09-22 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
CA2614766A1 (en) * 2005-07-11 2007-01-18 Macrogenics, Inc. Methods of treating autoimmune disease using humanized anti-cd16a antibodies
WO2008112325A2 (en) 2007-03-15 2008-09-18 Biogen Idec Ma Inc. Treatment of autoimmune disorders
GB0623539D0 (en) 2006-11-24 2007-01-03 Avidex Ltd Polypeptides
US20090016935A1 (en) 2007-07-09 2009-01-15 Andrianov Alexander K Coating formulations including polyphosphazene polyelectrolytes and biologically active agents and asperities coated with such formulations
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
WO2009061853A2 (en) 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
EP2382228B2 (en) * 2009-01-21 2026-01-07 Amgen Inc. Compositions and methods of treating inflammatory and autoimmune diseases
CA2750533A1 (en) * 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
CA2781539C (en) 2009-11-23 2021-07-20 Amgen Inc. Monomeric antibody fc
CN102939303A (zh) * 2009-12-22 2013-02-20 诺瓦提斯公司 四价cd47-抗体恒定区融合蛋白用于治疗
EA034333B1 (ru) 2010-11-30 2020-01-29 Дженентек, Инк. Варианты антитела для переноса соединения через гематоэнцефалический барьер
TWI666027B (zh) * 2011-02-10 2019-07-21 羅齊克雷雅公司 突變介白素-２多肽
CA2830254C (en) 2011-03-16 2019-09-10 Amgen Inc. Fc variants
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CA2861122A1 (en) 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
EP3594239B1 (en) 2012-05-21 2024-10-30 F. Hoffmann-La Roche AG Methods for improving safety of blood-brain barrier transport
US9546203B2 (en) * 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
AU2014233494B2 (en) * 2013-03-15 2018-10-04 Genentech, Inc. IL-22 polypeptides and IL-22 Fc fusion proteins and methods of use
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
SMT201900301T1 (it) 2019-07-11
US20180237489A1 (en) 2018-08-23
JP2025066162A (ja) 2025-04-22
LT2970423T (lt) 2019-05-27
LT2970441T (lt) 2019-06-10
PT2970423T (pt) 2019-07-23
US20140286898A1 (en) 2014-09-25
WO2014153111A2 (en) 2014-09-25
JP2016518823A (ja) 2016-06-30
PL2970423T3 (pl) 2019-10-31
CY1121767T1 (el) 2020-07-31
CN105143253B (zh) 2021-02-19
TW202115106A (zh) 2021-04-16
WO2014153063A1 (en) 2014-09-25
EP2970441B1 (en) 2019-03-06
MX2015012890A (es) 2015-12-03
TR201908362T4 (tr) 2019-06-21
ES2737598T3 (es) 2020-01-15
ES2720225T3 (es) 2019-07-18
UA119140C2 (uk) 2019-05-10
AU2014236281B2 (en) 2018-03-08
SI2970441T1 (sl) 2019-07-31
KR20220101009A (ko) 2022-07-18
EP2970441A1 (en) 2016-01-20
TWI687435B (zh) 2020-03-11
CA3149348C (en) 2023-09-12
US9932380B2 (en) 2018-04-03
CA2905141A1 (en) 2014-09-25
TWI784288B (zh) 2022-11-21
US10562950B2 (en) 2020-02-18
CA3149348A1 (en) 2014-09-25
US20210094997A1 (en) 2021-04-01
BR112015023145A2 (pt) 2017-11-21
DK2970441T3 (da) 2019-06-03
JP6450365B2 (ja) 2019-01-09
MY172991A (en) 2019-12-17
MY202248A (en) 2024-04-19
NZ751148A (en) 2021-05-28
BR112015022440B1 (pt) 2022-08-16
PH12015502051B1 (en) 2016-01-18
MX2015012912A (es) 2015-12-03
CN105143253A (zh) 2015-12-09
MX372880B (es) 2020-07-08
US10093711B2 (en) 2018-10-09
RS58854B1 (sr) 2019-07-31
SG11201507574VA (en) 2015-10-29
US20180319859A1 (en) 2018-11-08
US9580486B2 (en) 2017-02-28
IL241622B (en) 2020-09-30
EP2970441A4 (en) 2016-11-23
TR201910802T4 (tr) 2019-08-21
AR095541A1 (es) 2015-10-21
KR102418771B1 (ko) 2022-07-08
EA201591731A1 (ru) 2016-04-29
JP2016514161A (ja) 2016-05-19
HUE044321T2 (hu) 2019-10-28
TWI709572B (zh) 2020-11-11
PT2970441T (pt) 2019-06-11
JP2023053148A (ja) 2023-04-12
PE20151763A1 (es) 2015-12-10
JP2021040630A (ja) 2021-03-18
SMT201900415T1 (it) 2019-09-09
MA38477B1 (fr) 2019-05-31
EP2970423A2 (en) 2016-01-20
JP7227951B2 (ja) 2023-02-22
UY40090A (es) 2023-04-14
MX366854B (es) 2019-07-26
MA38477A1 (fr) 2017-09-29
JO3796B1 (ar) 2021-01-31
CL2015002686A1 (es) 2016-04-15
HRP20191075T1 (hr) 2019-09-20
JP2019058182A (ja) 2019-04-18
TN2015000416A1 (en) 2017-01-03
US20140343252A1 (en) 2014-11-20
CR20150557A (es) 2015-11-10
DK2970423T3 (da) 2019-07-08
EA201591766A1 (ru) 2016-02-29
US20240327485A1 (en) 2024-10-03
EA034326B1 (ru) 2020-01-28
AU2014236281A1 (en) 2015-09-24
BR112015022440A2 (pt) 2017-10-24
MA49207B1 (fr) 2022-08-31
AU2014236316A9 (en) 2018-11-08
UY35454A (es) 2014-09-30
US20170081382A1 (en) 2017-03-23
TW201522366A (zh) 2015-06-16
IL241349A0 (en) 2015-11-30
HRP20190970T1 (hr) 2019-07-26
CA2906708A1 (en) 2014-09-25
US10829535B2 (en) 2020-11-10
RS58791B1 (sr) 2019-07-31
CL2015002669A1 (es) 2016-09-09
HK1220695A1 (en) 2017-05-12
CA2906708C (en) 2022-05-03
KR20230157526A (ko) 2023-11-16
US9546203B2 (en) 2017-01-17
EA032863B1 (ru) 2019-07-31
CN105358570B (zh) 2019-11-12
CN105358570A (zh) 2016-02-24
HUE043488T2 (hu) 2019-08-28
KR20150130342A (ko) 2015-11-23
SI2970423T1 (sl) 2019-08-30
CR20200004A (es) 2020-03-11
JP6480409B2 (ja) 2019-03-13
ME03437B (me) 2020-01-20
KR102219124B1 (ko) 2021-02-22
WO2014153111A3 (en) 2014-11-13
US20170137485A1 (en) 2017-05-18
NZ712066A (en) 2021-05-28
KR20250002742A (ko) 2025-01-07
PL2970441T3 (pl) 2019-09-30
US11976102B2 (en) 2024-05-07
KR20150127185A (ko) 2015-11-16
TW202005979A (zh) 2020-02-01
EP2970423B1 (en) 2019-04-24
MA49207A1 (fr) 2021-09-30
PH12015502051A1 (en) 2016-01-18
CY1121823T1 (el) 2020-07-31
AP2015008737A0 (en) 2015-09-30
IL241349B (en) 2018-08-30
SG11201507420UA (en) 2015-10-29
AU2014236316B2 (en) 2018-11-01
AU2014236316A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
ME03482B (me) POLIPETPIDI KOJI SADRŽE NEGLIKOZILISANI Fc
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
EP2995264A4 (en) Clip unit
DK3077047T3 (da) Aramcholsalte
DK3052081T3 (da) Pastil
LT3038654T (lt) Naujas panaudojimas
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK2956698T5 (da) Bindestrimler
EP3525454C0 (en) DISPLAY DEVICE
DK2946640T3 (da) Langmuir-probe
EP2943489A4 (en) DEUTERATED MOMELOTINIB
LT3030259T (lt) Peptidai
HRP20181183T1 (hr) Biciklički spoj koji sadrži sumpor
DE102013106534B8 (de) Chromatographiepipettenspitze
EP2991647A4 (en) DEUTERED AMLEXANOX
EP2970310A4 (en) 5-BROMO-indirubins
EP2853297A4 (en) kendama
DK3071227T3 (da) Fiskevaccine
DE112014001252A5 (de) Aufbissschiene
DK3086679T3 (da) Sportssko
DK2981168T3 (da) Laminitiskile
EP2989503A4 (en) SCREEN
FI10138U1 (fi) Kelkkateltta